References
- Witt CM, Balneaves LG, Cardoso MJ, et al. A comprehensive definition for integrative oncology. J Natl Cancer Inst Monogr. 2017 Nov;2017(52). doi: 10.1093/jncimonographs/lgx012
- Phi LTH, Sari IN, Yang Y-G, et al. Cancer Stem cells (CSCs) in drug resistance and their therapeutic Implications in cancer treatment. Stem Cells Int. 2018;2018:1–16. doi: 10.1155/2018/5416923
- Tappia PS, Ramjiawan B. Biomarkers for early detection of cancer: molecular aspects. Int J Mol Sci. 2023;24(6):5272. Switzerland, Mar. doi: 10.3390/ijms24065272
- Di Nicolantonio F, Vitiello PP, Marsoni S, et al. Precision oncology in metastatic colorectal cancer — from biology to medicine. Nat Rev Clin Oncol. 2021;18(8):506–525. doi: 10.1038/s41571-021-00495-z
- Singla P, Musyuni P, Aggarwal G, et al. Precision medicine: an emerging Paradigm for improved diagnosis and safe therapy in pediatric oncology. Cureus. 2021 Jul;13(7):e16489. doi: 10.7759/cureus.16489
- Brockley LJ, Souza VGP, Forder A, et al. Sequence-based platforms for discovering biomarkers in liquid biopsy of non-small-cell lung cancer. Cancers (Basel). 2023 Apr;15(8):2275. doi: 10.3390/cancers15082275
- Huang L, Ma F, Chapman A, et al. Single-cell whole-genome amplification and sequencing: methodology and applications. Annu Rev Genomics Hum Genet. 2015;16(1):79–102. doi: 10.1146/annurev-genom-090413-025352
- Szász I, Kiss T, Mokánszki A, et al. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays. Mol Cell Probes. 2023;67:101888. doi: 10.1016/j.mcp.2022.101888
- Babu M, Snyder M. Multi-omics profiling for health. Mol & Cell Proteomics. 2023 Jun;22(6):100561. doi: 10.1016/j.mcpro.2023.100561
- Hong M, Tao S, Zhang L, et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13(1):166. doi: 10.1186/s13045-020-01005-x
- Arjmand B, Hamidpour SK, Tayanloo-Beik A, et al. Machine learning: a New prospect in multi-omics data analysis of cancer. Front Genet. 2022;13:824451. doi: 10.3389/fgene.2022.824451
- Zhao S, Li J, Xia Q, et al. New perspectives for targeting therapy in ALK-positive human cancers. Oncogene. 2023;42(24):1959–1969. doi: 10.1038/s41388-023-02712-8
- Rager T, Eckburg A, Patel M, et al. Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies. Cancers (Basel). 2022;14(15):3779. doi: 10.3390/cancers14153779
- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi: 10.1038/s41577-020-0306-5
- Branchoux S, Sofeu CL, Gaudin A-F, et al. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open. 2022 Feb;7(1):100340. doi: 10.1016/j.esmoop.2021.100340
- Gallivanone F, Bertoli G, Porro D. Radiogenomics, breast cancer diagnosis and characterization: Current status and Future directions. Methods Protoc. 2022 Oct;5(5). doi: 10.3390/mps5050078.
- Gallivanone F, Cava C, Corsi F, et al. In Silico Approach for the Definition of radiomiRNomic Signatures for Breast Cancer Differential Diagnosis. Int J Mol Sci. 2019 Nov;20(23). doi: 10.3390/ijms20235825.
- Gatenby RA, Silva AS, Gillies RJ, et al. Adaptive therapy. Cancer Res. 2009 Jun;69(11):4894–4903. doi: 10.1158/0008-5472.CAN-08-3658
- Beckman RA, Schemmann GS, Yeang C-H. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A. 2012 Sep;109(36):14586–14591. doi: 10.1073/pnas.1203559109
- Rockne RC, Hawkins-Daarud A, Swanson KR, et al. The 2019 mathematical oncology roadmap. Phys Biol. 2019 Jun;16(4):41005. doi: 10.1088/1478-3975/ab1a09
- Schmitt MW, Kennedy SR, Salk JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012 Sep;109(36):14508–14513. doi: 10.1073/pnas.1208715109
- Loeb LA, Kohrn BF, Loubet-Senear KJ, et al. Extensive subclonal mutational diversity in human colorectal cancer and its significance. Proc Natl Acad Sci U S A. 2019 Dec;116(52):26863–26872. doi: 10.1073/pnas.1910301116
- Beckman RA, Loeb LA. Rare mutations in cancer drug resistance and implications for therapy. Clin Pharmacol Ther. 2020;108(3):437–439. doi: 10.1002/cpt.1938